Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

Cancer Medicine

Volumn 4, Issue 8, 2015, Pages 1205-1213

  Gibney, Geoffrey T ^a   Gauthier, Geneviève ^b   Ayas, Charles ^b   Galebach, Philip ^b   Wu, Eric Q ^b   Abhyankar, Sarang ^c   Reyes, Carolina ^c   Guérin, Annie ^b   Yim, Yeun Mi ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ANALYSIS GROUP   (United States)

^c GENENTECH INC   (United States)

Author keywords

BRAF mutation; Brain metastases; Melanoma brain metastases; Metastatic melanoma; Vemurafenib

Indexed keywords

B RAF KINASE; CORTICOSTEROID; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; AGED; BRAIN NEOPLASMS; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85006219333     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.475     Document Type: Article

References (33)

1. Chamberlain, M. C. 2010. Brain metastases: a medical neuro-oncology perspective. Expert Rev. Neurother. 10:563-573.
2. Carlino, M., M. Atkins, and C. Warneke . 2010. Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ & the US) study. Pigment Cell Melanoma Res 23: 874-1004.
3. Lotze, M., R. Dallal, J. M. Kirkwood, and J. Flickinger . 2001. Pp. 2012-2069 in Cancer: principles & practice of oncology, 6th ed. Lippincott Williams and Wilkins, Philadelphia.
4. Lagerwaard, F. J., P. C. Levendag, P. J. Nowak, W. M. Eijkenboom, P. E. Hanssens, and P. I. Schmitz . 1999. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int. J. Radiat. Oncol. Biol. Phys. 43:795-803.
5. Fife, K. M., M. H. Colman, G. N. Stevens, I. C. Firth, D. Moon, K. F. Shannon, et al. 2004. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22: 1293-1300.
6. Staudt, M., K. Lasithiotakis, U. Leiter, F. Meier, T. Eigentler, M. Bamberg, et al. 2010. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102:1213-1218.
7. Gibney, G. T., P. A. Forsyth, and V. K. Sondak . 2012. Melanoma in the brain: biology and therapeutic options. Melanoma Res. 22: 177-183.
8. Ewend, M. G., D. E. Morris, L. A. Carey, A. M. Ladha, and S. Brem . 2008. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J. Natl. Compr. Canc. Netw. 6: 505-513; quiz 514.
9. Mornex, F., L. Thomas, P. Mohr, A. Hauschild, M. M. Delaunay, T. Lesimple, et al. 2003. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 13:97-103.
10. Margolin, K., B. Atkins, A. Thompson, S. Ernstoff, J. Weber, L. Flaherty, et al. 2002. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the cytokine working group. J. Cancer Res. Clin. Oncol. 128:214-218.
11. Hwu, W.-J., E. Lis, J. H. Menell, K. S. Panageas, L. A. Lamb, J. Merrell, et al. 2005. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103:2590-2597.
12. Atkins, M. B., J. A. Sosman, S. Agarwala, T. Logan, J. I. Clark, M. S. Ernstoff, et al. 2008. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113:2139-2145.
13. Agarwala, S. S., J. M. Kirkwood, M. Gore, B. Dreno, N. Thatcher, B. Czarnetski, et al. 2004. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J. Clin. Oncol. 22:2101-2107.
14. Guirguis, L. M., J. C. Yang, D. E. White, S. M. Steinberg, D. J. Liewehr, S. A. Rosenberg, et al. 2002. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J. Immunother. 25:82-87.
15. Margolin, K., M. S. Ernstoff, O. Hamid, D. Lawrence, D. McDermott, I. Puzanov, et al. 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13:459-465.
16. Hong, J. J., S. A. Rosenberg, M. E. Dudley, J. C. Yang, D. E. White, J. A. Butman, et al. 2010. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16:4892-4898.
17. Long, G. V., U. Trefzer, M. A. Davies, R. F. Kefford, P. A. Ascierto, P. B. Chapman, et al. 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13:1087-1095.
18. Long, G. V., A. M. Menzies, A. M. Nagrial, L. E. Haydu, A. L. Hamilton, G. J. Mann, et al. 2011. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29:1239-1246.
19. Rizos, H., A. M. Menzies, G. M. Pupo, M. S. Carlino, C. Fung, J. Hyman, et al. 2014. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20:1965-1977.
20. Bollag, G., P. Hirth, J. Tsai, J. Zhang, P. N. Ibrahim, H. Cho, et al. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599.
21. Salama, A. K. S., and K. T. Flaherty . 2013. BRAF in melanoma: current strategies and future directions. Clin. Cancer Res. 19:4326-4334.
22. Dummer, R., S. M. Goldinger, C. P. Turtschi, N. B. Eggmann, O. Michielin, L. Mitchell, et al. 2014. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur. J. Cancer 50:611-621.
23. Kefford, G. M. R., Mi. Maio, A. Arance, P. Nathan, C. Blank, M. F. Avril, et al. 2013. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. Presented at the 10th International Meeting Society Melanoma Research, Philadelphia, Pennsylvania, USA.
24. Genentech, Inc. 2014. Vemurafenib [package insert]. Genentech, Inc, South San Francisco, CA.
25. Larkin, J., M. Del Vecchio, P. A. Ascierto, I. Krajsova, J. Schachter, B. Neyns, et al. 2014. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 15:436-444.
26. Davies, M. A., P. Liu, S. McIntyre, K. B. Kim, N. Papadopoulos, W.-J. Hwu, et al. 2011. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687-1696.
27. Eigentler, T. K., A. Figl, D. Krex, P. Mohr, C. Mauch, K. Rass, et al. 2011. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117:1697-1703.
28. Larkin, J., P. A. Ascierto, B. Dréno, V. Atkinson, G. Liszkay, M. Maio, et al. 2014. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma, " N. Engl. J. Med. 371:1867-1876.
29. Long, G. V., D. Stroyakovskiy, H. Gogas, E. Levchenko, de Braud F., J. Larkin, et al. 2014. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N. Engl. J. Med. 371:1877-1888.
30. Robert, C., B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz, D. Stroiakovski, et al. 2014. Improved overall survival in melanoma with combined Dabrafenib and Trametinib. N. Engl. J. Med. 372:30-39.
31. Flaherty, K. T., C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, et al. 2012. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367:107-114.
32. Ribas, A., P. Hersey, M. R. Middleton, H. Gogas, K. T. Flaherty, V. K. Sondak, et al. 2012. New challenges in endpoints for drug development in advanced melanoma. Clin. Cancer Res. 18:336-341.
33. Kefford, R., R. J. Sullivan, W. H. Miller, E. M. Elez, D. Tan, K. B. Kim, et al. 2014. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results. J. Transl. Med. 12(Suppl. 1):P5.